Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. - Normandie Université Accéder directement au contenu
Article Dans Une Revue Alimentary Pharmacology & Therapeutics (Suppl) Année : 2020

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.

Résumé

The prevalence of inflammatory bowel diseases (IBD) is high in women of childbearing age. Achieving clinical remission from conception to delivery using current medications is a major issue in IBD.
Fichier non déposé

Dates et versions

hal-03138226 , version 1 (11-02-2021)

Identifiants

Citer

Pauline Wils, Philippe Seksik, Carmen Stefanescu, Stephane Nancey, Matthieu Allez, et al.. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.. Alimentary Pharmacology & Therapeutics (Suppl), 2020, ⟨10.1111/apt.16192⟩. ⟨hal-03138226⟩
52 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More